Cancel
Loïc Vincent
Chief Scientific Officer
@
Affini-T Therapeutics
About Loïc Vincent
Loïc Vincent is the Chief Scientific Officer known for his significant contributions to oncology, particularly in presenting preclinical and clinical-stage data on KRAS and p53 mutations at the AACR Annual Meeting 2024.
Known information
Loïc Vincent holds the position of Chief Scientific Officer and has made notable advancements in the field of oncology. At the American Association for Cancer Research (AACR) Annual Meeting in 2024, Vincent presented preclinical data focused on oncogenic driver programs targeting mutations KRAS G12D and p53 R175H. Additionally, he showcased two trial-in-progress posters related to Phase 1 clinical-stage programs targeting the KRAS G12V mutation. His work is pivotal in advancing the understanding and potential treatments of these specific oncogenic mutations.
About Affini-T Therapeutics
Affini-T Therapeutics, based in Watertown, MA, develops TCR-based immunotherapies for solid tumors, focusing on oncogenic mutations such as KRAS and p53.
Report inaccurate information
